28332360|t|Entecavir to Telbivudine Switch Therapy in Entecavir - Treated Patients with Undetectable Hepatitis B Viral DNA
28332360|a|This study examined 2-year outcome of consecutive therapy using entecavir (ETV) followed by telbivudine (LdT) in subjects with undetectable hepatitis B virus (HBV) DNA level and normal alanine aminotransferase level after the initial 6 months of ETV treatment. Sixty subjects were randomized to continue with ETV or switch to LdT. Significant difference in baseline characteristics was not found between the two groups. Persistent HBV DNA level of 20-60 IU/mL in three consecutive samples collected three months apart or singly measured HBV DNA level of >60 IU/mL was defined as virological rebound. During 96 weeks of follow-up, all subjects of the ETV -only group (n=30) resulted in undetectable HBV DNA level. On the other hand, 83.3% (n=25) of the LdT - switched group showed treatment success. Virological rebound time varied from week 24 to 84 after switching to LdT. HBV DNA level was 180 to 2940 IU/mL at rebound time. All subjects with virological rebound (n=5) showed drug-resistant mutation: three had mutation rtM204I, and two had mutation rtM204V. Consecutive treatment using ETV followed by LdT showed virological rebound in 16.7% of subjects during 96 weeks of follow-up. HBV DNA negativity during initial ETV therapy could not be achieved in patients who switched to LdT. Consecutive treatment using ETV followed by lamivudine was ineffective for treating chronic hepatitis B. LdT was found as a more potent antiviral agent than lamivudine. However, this conclusion requires larger-scale, long-term prospective reviews of the treatment effects of ETV - LdT switch therapy.
28332360	0	9	Entecavir	T103	UMLS:C0971023
28332360	13	24	Telbivudine	T103	UMLS:C1453933
28332360	25	31	Switch	T058	UMLS:C2936279
28332360	32	39	Therapy	T058	UMLS:C0087111
28332360	43	52	Entecavir	T103	UMLS:C0971023
28332360	77	89	Undetectable	T201	UMLS:C3827727
28332360	162	169	therapy	T058	UMLS:C0087111
28332360	176	185	entecavir	T103	UMLS:C0971023
28332360	187	190	ETV	T103	UMLS:C0971023
28332360	204	215	telbivudine	T103	UMLS:C1453933
28332360	217	220	LdT	T103	UMLS:C1453933
28332360	225	233	subjects	T098	UMLS:C0080105
28332360	239	251	undetectable	T201	UMLS:C3827727
28332360	297	327	alanine aminotransferase level	T058	UMLS:C0201836
28332360	358	361	ETV	T103	UMLS:C0971023
28332360	362	371	treatment	T058	UMLS:C0087111
28332360	379	387	subjects	T098	UMLS:C0080105
28332360	421	424	ETV	T103	UMLS:C0971023
28332360	428	434	switch	T058	UMLS:C2936279
28332360	438	441	LdT	T103	UMLS:C1453933
28332360	469	493	baseline characteristics	T033	UMLS:C1290922
28332360	731	740	follow-up	T058	UMLS:C1522577
28332360	746	754	subjects	T098	UMLS:C0080105
28332360	762	765	ETV	T103	UMLS:C0971023
28332360	797	809	undetectable	T201	UMLS:C3827727
28332360	864	867	LdT	T103	UMLS:C1453933
28332360	870	878	switched	T058	UMLS:C2936279
28332360	923	930	rebound	T033	UMLS:C0549262
28332360	923	930	rebound	T033	UMLS:C0549262
28332360	968	977	switching	T058	UMLS:C2936279
28332360	981	984	LdT	T103	UMLS:C1453933
28332360	1025	1032	rebound	T033	UMLS:C0549262
28332360	1043	1051	subjects	T098	UMLS:C0080105
28332360	1069	1076	rebound	T033	UMLS:C0549262
28332360	1090	1104	drug-resistant	T038	UMLS:C0013203
28332360	1105	1113	mutation	T038	UMLS:C0596611
28332360	1125	1133	mutation	T038	UMLS:C0596611
28332360	1134	1141	rtM204I	T017	UMLS:C1335440
28332360	1155	1163	mutation	T038	UMLS:C0596611
28332360	1164	1171	rtM204V	T017	UMLS:C1335440
28332360	1185	1194	treatment	T058	UMLS:C0087111
28332360	1201	1204	ETV	T103	UMLS:C0971023
28332360	1217	1220	LdT	T103	UMLS:C1453933
28332360	1240	1247	rebound	T033	UMLS:C0549262
28332360	1260	1268	subjects	T098	UMLS:C0080105
28332360	1288	1297	follow-up	T058	UMLS:C1522577
28332360	1307	1317	negativity	T033	UMLS:C1513916
28332360	1333	1336	ETV	T103	UMLS:C0971023
28332360	1337	1344	therapy	T058	UMLS:C0087111
28332360	1383	1391	switched	T058	UMLS:C2936279
28332360	1395	1398	LdT	T103	UMLS:C1453933
28332360	1412	1421	treatment	T058	UMLS:C0087111
28332360	1428	1431	ETV	T103	UMLS:C0971023
28332360	1444	1454	lamivudine	T103	UMLS:C0209738
28332360	1475	1483	treating	T058	UMLS:C0087111
28332360	1484	1503	chronic hepatitis B	T038	UMLS:C0524909
28332360	1505	1508	LdT	T103	UMLS:C1453933
28332360	1536	1551	antiviral agent	T103	UMLS:C0003451
28332360	1557	1567	lamivudine	T103	UMLS:C0209738
28332360	1627	1646	prospective reviews	T062	UMLS:C0033522
28332360	1654	1663	treatment	T058	UMLS:C0087111
28332360	1675	1678	ETV	T103	UMLS:C0971023
28332360	1681	1684	LdT	T103	UMLS:C1453933
28332360	1685	1691	switch	T058	UMLS:C2936279
28332360	1692	1699	therapy	T058	UMLS:C0087111